IMV is developing a pipeline of novel therapeutic and preventive approaches for cancer and other serious diseases. Our proprietary platform provides a solution for product candidates with the potential to produce more rapid, robust and sustained immune responses. We have leveraged this technology, along with partnerships with world-class researchers, to build a diverse and growing pipeline of combination immunotherapies for difficult-to-treat cancers and hard-to-address infectious disease challenges.
Our development pipeline currently includes multiple clinical-stage programs, each in areas of significant unmet medical needs. In our immuno-oncology programs, we are focused on advancing combination immunotherapies, as we believe that it is necessary to attack difficult cancers from multiple pathways. Cancers continue to persist because of their uncanny ability to evolve – to create resistances that continually evade the immune system and survive even the most modern treatment advances for the vast majority of patients. Activating T cells is a crucial component—but one of several inherent in our strategy to ‘out-think’ cancer. Therefore, our pipeline includes combinations with cyclophosphamide – which can be used as an immune modulator, as well as other agents, such as anti-PD-1 inhibitors that can act synergistically with our T cell activating technology to reduce systemic resistance and bolster targeted anti-cancer responses.
Our cancer programs are evaluating the use of our lead candidate, DPX-Survivac, in multiple combination regimens for advanced ovarian cancer, including some of the earliest triple-combination immunotherapy trials in this tumor type, and in diffuse large B-cell lymphoma (DLBCL). DPX-Survivac is a T cell activating immunotherapy that targets survivin, an antigen present in more than 20 types of solid tumor and hematologic cancers. We are working with several clinical partners to advance DPX-Survivac, including Merck.
Our DPX-E7 candidate is being developed in combination with cyclophosphamide to stimulate the human immune system to mount an anti-cancer T cell response against human papillomavirus (HPV). HPV is the leading cause of cervical cancer and is implicated in anal, vulva, vaginal, penile and oropharyngeal cancers. We are working in conjunction with the Dana-Farber Cancer Institute to develop DPX-E7 to address these unmet medical needs.
DPX-RSV is being evaluated in respiratory syncytial virus (RSV), a condition that has long confounded our industry, and which causes 64 million cases of severe respiratory infection around the world each year.
1. Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok. Combination immunotherapy: a road map. Journal for ImmunoTherapy of Cancer (2017). 5:16 DOI 10.1186/s40425-017-0218-5